00719 SHANDONG XINHUA
- 5.440
- +0.100+1.87%
SHANDONG XINHUA News
SHANDONG XINHUA: Annual Report 2023
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: Announcement Notice of Board Meeting
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Cefaclor Capsules of Wholly-owned Subsidiary Passing the Generics Consistency Evaluation
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Peramivir Injection Having Obtained the Notification of Approval of Supplementary Drug Application
SHANDONG XINHUA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
SHANDONG XINHUA: Final Dividend for the Year Ended 31 December 2023
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: Proposed Amendments to the Articles of Association
SHANDONG XINHUA: Proposed Change of Auditors
SHANDONG XINHUA: Announcement for 2023 Annual Results
SHANDONG XINHUA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SHANDONG XINHUA: Announcement Notice of Board Meeting
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Ibuprofen Sustained Release Capsules Obtaining the Drug Registration Certificate
SHANDONG XINHUA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
SHANDONG XINHUA: Overseas Regulatory Announcement-Announcement on Prednisone Having Obtained the Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient
SHANDONG XINHUA: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
SHANDONG XINHUA: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Analysis
Price Target
No Data
